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Background:  Management advice for women with lobular carcinoma in situ (LCIS) 
is hampered by the lack of accurate personalised risk estimates for subsequent 
invasive breast cancer (BC).  Prospective validation of the only tool that estimates 
individual BC risk for a woman with LCIS, the International Breast Cancer 
Intervention Study Risk Evaluation Tool (IBIS-RET), is lacking.  Methods: Using 
population-based cancer registry data for 732 women with LCIS, the calibration and 
discrimination accuracy of IBIS-RET Version 7.2 were assessed.  Results:  The 
mean observed 10-year risk of invasive BC was 14.1% (95% CI:11.3%-17.5%). IBIS-
RET overestimated invasive BC risk (p= 0.0003) and demonstrated poor 
discriminatory accuracy (AUC 0.54, 95% CI: 0.48 – 0.62).  Conclusion: Clinicians 
should understand that IBIS-RET Version 7.2 may overestimate 10-year invasive BC 
risk for Australian women with LCIS. The newer IBIS-RET Version 8.0, released 
September 2017, includes mammographic density and may perform better, but 
validation is needed. 
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Women diagnosed with lobular carcinoma in-situ (LCIS) have an elevated risk of 
subsequent invasive breast cancer (BC) (Page et al, 1991) that increases by about 
1% every year after diagnosis to 13% after 10 years, 11%-26% at 15 years (Page et 
al, 1991) (Chuba et al, 2005) (King et al, 2015) and 21%-26% risk after 20 years. 
(Bodian et al, 1996), (To et al, 2014) 
 
Most are managed with observation alone (Degnim & King, 2013), but American 
Society of Clinical Oncology and Cancer Australia guidelines recommend that risk-
reducing medications, specifically selective estrogen receptor modulators (SERM) or 
aromatase inhibitors (AI) (the latter only in postmenopausal women), be discussed 
with LCIS patients. (Fisher et al, 1998) (Vogel et al, 2006) (Visvanathan et al, 2013) 
(Cancer Australia, 2016) Risk-reducing bilateral mastectomy is pursued by only a 
minority of LCIS patients. (Oppong & King, 2011) Informed decision-making would 
be facilitated by accurate personalised risk estimates for future invasive BC.  
 
The International Breast Cancer Intervention Study Risk Evaluation Tool (IBIS-RET) 
is the only tool available to estimate risk for an individual woman with LCIS. (Tyrer et 
al, 2004) (Amir et al, 2010) (U.S. Preventive Services Task Force, 2016) Although 
validated in other populations, (Amir et al, 2003) (Jacobi et al, 2009) (Quante et al, 
2012) IBIS-RET, to our knowledge, it has not been validated in LCIS patients.  Using 
population-based data, we prospectively examined the performance of IBIS-RET 





The Victorian Cancer Registry (VCR) has collected data on all cancer diagnoses in 
Victoria, Australia since 1982. It determines vital status of all registrants by record 
linkage to the state and national death registries. (Cancer Council Victoria, 2017a) 
De-identified data including dates of birth, death, LCIS and invasive BC diagnoses 
were obtained from the VCR for all women diagnosed with pure LCIS between 1982 
and 2015, when aged 20-70 years.  ‘Pure’ LCIS was defined as LCIS without 
previous or synchronous ductal carcinoma in-situ (DCIS) or invasive BC in either 
breast (including within 6 months after LCIS diagnosis). Women with other invasive 
cancer diagnoses (except non-melanotic skin cancer) prior to their pure LCIS 
diagnosis were excluded.  The study was approved by the Peter MacCallum Cancer 
Centre ethics committee.  
 
The calibration and discriminatory accuracy of the 10-year IBIS-RET Version 7.2 
estimates were assessed by comparing IBISRET-assigned risks with observed 
invasive BC incidence. To assess calibration, the mean IBIS-RET-assigned risk was 
compared with the mean 10-year observed invasive BC incidence in each IBIS-RET-
assigned risk group, using a chi-squared goodness-of-fit statistic, (Whittemore & 
Halpern, 2016) for the whole cohort (by tertiles) and also for two subgroups stratified 
by the diagnosis of LCIS before and at or after age 50 years. To evaluate 
discriminatory accuracy, the overall area under the receiver operating characteristic 
(ROC) curve for the development of invasive BC within 10 years of LCIS diagnosis 
was computed. RMAP (http://stanford.edu/~ggong/rmap/) and SAS software 9.4 
(SAS Institute, Cary, NC) were used. Data were censored at date of invasive BC 
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diagnosis, death and date that the most recently linked death data were considered 
complete (31st December 2015). Two exploratory analyses were also conducted; the 
first censored the data at date of any ductal carcinoma in situ (DCIS) diagnosis and 
the second included diagnosis of either invasive breast cancer and/or DCIS as the 
primary endpoint.  
 
Results: 
There were 732 eligible women (median age at LCIS 50 years, range 25-70 years, 
mean follow-up 9.8 years, range 0.04 - 33.9 years, total 4855 person-years), of 
whom 73 were diagnosed with invasive BC within 10 years after their LCIS. 10 
women died within 10 years without an invasive BC diagnosis, 293 women were 
invasive BC-free at 10 years and 356 women were last observed without invasive 
BC with less than 10 years follow-up. The mean observed risk of invasive BC at 10 
years was 14.1% (95% confidence interval (CI) 11.3%-17.5%), whilst the mean 
assigned IBIS-RET 10-year risk was 20.9%. 
 
Figure 1 shows the cumulative invasive BC incidence by 10-year IBIS-RET-assigned 
risk tertile (i.e. <18.8%, ≥18.8% - <23.5%, ≥23.5%).   
 
Figure 2 shows that the mean IBIS-RET-assigned invasive BC risks by tertile were 
significantly different to the observed BC incidence at 10 years (p= 0.0003). Overall 
the IBIS-RET Version 7.2 tended to overestimate invasive BC risk. When we 
compared the calibration for women below and above age 50 using internal cutpoints 
by age, we found it was well-calibrated for women diagnosed before age 50 years 
(p=0.13), but not for those diagnosed at or after age 50 years mainly owing to the 
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lack of fit and overestimation by IBIS-RET for older women in the highest quantile, 
(p=0.00007) (Figures 3A and 3B).  
 
The area under the ROC curve (AUC) for the IBIS-RET 10-year invasive BC risk 
estimates was 0.54 (95% CI: 0.48 – 0.62) overall, and 0.55 (95% CI: 0.44 – 0. 0.63) 
and 0.48 (95% CI: 0.38 – 0.57) for women diagnosed with LCIS before age 50 years 
and at or after age 50 years, respectively. 
 
Nine women were diagnosed with DCIS during the first 10 years after their LCIS 
diagnosis. The results were similar when the analyses were repeated either 
censoring at DCIS diagnosis or including the 9 cases of DCIS along with the invasive 
BC cases in the primary endpoint (Supplementary Figure 1). 
  
Discussion: 
In this population-based study of women with LCIS, the IBIS-RET Version 7.2 tended 
to overestimate 10-year invasive BC risk and had poor discriminatory accuracy. 
However this study had several limitations that may have contributed to this finding.  
 
The lack of information in our dataset regarding uptake of bilateral mastectomy or 
risk-reducing medication after LCIS diagnosis could have resulted in our study 
erroneously finding that IBIS-RET overestimates BC risk. However, uptake of these 
interventions is historically very low in Australia, even in very high-risk women 




Histopathological diagnostic thresholds for atypical hyperplasia (AH) and LCIS have 
changed over time (Ginter & D’Alfonso, 2017). If some of the cases included in this 
study were in fact AH misclassified as LCIS, this could have contributed to our 
finding that IBIS-RET V7.2 overestimates BC risk, because AH confers a lower BC 
risk than LCIS. No pathology review of cases was undertaken by the authors or the 
VCR.  
 
The IBIS-RET model is calibrated to UK BC incidence rates for 2008-2010 
(Supplementary Table 1) (Cuzick, 2017)). Although our study covers Victorian 
women over a period from 1982-2015, the average age-specific BC incidence figures 
for these Victorian women closely resembled those used in the IBIS-RET model, 
except for the lower incidence in those aged 50 years and over (Supplementary 
Table 1) (Cancer Council Victoria, 2017b). This could have contributed to the 
overestimation and poorer calibration in our dataset for women diagnosed with LCIS 
at and over age 50 years, but it is unlikely to completely explain our findings.  
 
Overdiagnoses from mammographic screening could have influenced our findings. 
However, Victorian women aged 50 years and over are screened 2-yearly as 
opposed to 3-yearly in the UK and this higher screening frequency should, if 
anything have resulted in a higher invasive BC incidence when compared to the UK 
population, but this was not observed in those aged older than 50 years 




Patient migration out of Victoria after LCIS diagnosis would mean that some 
subsequent invasive breast cancers were not captured in the VCR data. Using 
aggregate data from the Australian Institute of Health and Welfare, we estimated that 
this interstate migration would have resulted in approximately 3 cases of invasive 
cancer being missed in our dataset, which could in part have contributed to our 
finding that IBIS-RET overestimates BC risk. 
 
The study dataset also did not include information on other BC risk factors, but 
because IBIS-RET Version 7.2 relies only on age to estimate subsequent BC risk in 
women with LCIS, this would not have impacted our findings. In fact there are 
conflicting reports on whether age at LCIS diagnosis affects subsequent BC risk. 
One study reported that the relative risk of BC tended to decrease with increasing 
age at LCIS diagnosis (Bodian et al, 1996). Conversely, according to King et al (King 
et al, 2015), risk factors like family history, age and breast density were not 
associated with BC risk in women with LCIS. Instead, the authors found that 
chemoprevention was the major factor associated with lower BC risk (Hazard ratio, 
0.27; 95% CI, 0.15 to 0.50). They also performed a subgroup nested case-control 
analysis, which showed that the volume of LCIS, which was defined as the ratio of 
slides with LCIS to total number of slides reviewed, was associated with BC 
development (p=0.008). Therefore, volume of LCIS might provide further risk 
stratification in women with LCIS.  
 
Mammographic density is an important risk factor for breast cancer and has been 
shown to refine the IBIS-RET model in predicting BC risk for women at increased 
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risk, although not specifically in women with LCIS. (Warwick et al, 2014) A 
subsequent study using a UK prospective BC screening cohort showed that using 
mammographic density with the IBIS-RET improved the accuracy of BC risk 
prediction.  (Brentnall et al, 2015) 
  
Since starting this study, IBIS-RET, Version 8 (Cuzick, 2017) has been released 
(September 2017).  For women with LCIS, Version 8 differs from Version 7.2 in that 
it now uses cancer family history and mammographic density (if available) to predict 
BC risk, as well as age at diagnosis of LCIS. The addition of cancer family history 
means that, in the absence of mammographic density information, IBIS-RET Version 
8 will always provide the same or higher 10-year BC risk estimates as Version 7.2 
(which we have shown here already tends to overestimate risk). However, if 
mammographic density is known to be low, the risk estimate provided by Version 8 
may be lower than that provided by Version 7.2. (Brentnall et al, 2015) A validation 
study of IBIS-RET Version 8, using a dataset of women with LCIS and known 
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